Special to DG News NEW YORK, NY — May 19, 2002 —
More than 90 percent of patients in the VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial were able to achieve diastolic blood pressure to goal, according to preliminary, one-year results presented in a poster presentation here Saturday during the 17th annual meeting of the American Society of Hypertension.
“In addition, we have been able to lower systolic blood pressure to goal in more than half of the patients,” said Dr. Stevo Julius, professor of medicine and physiology, and Frederick G.L. Huetwel professor of hypertension, University of Michigan, Ann Arbor, Michigan, United States.
Dr. Julius said a look at the two-year data indicates that doctors are making further progress in reducing the level of hypertension. The from the unblinded, ongoing VALUE trial compared the ability of valsartan — an angiotensin II receptor blocker — and amlodipine — a calcium channel blocker — to protect patients against cardiovascular events.
The study enrolled 15,314 patients from 31 countries, including 3676 patients from the United States, 1557 from Germany, 1095 from Italy, 887 from the United Kingdom, 881 from France, and 764 from Canada. Patients from Africa, Asia, Oceania and South America were also in the cohort.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!